Sun Pharmaceutical Industries Ltd (SUN.BO)
22 Sep 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|78||2012||Non-Executive and Non-Independent Chairman of the Board|
|2017||Chief Financial Officer|
|2011||Compliance Officer, Company Secretary|
|62||2012||Managing Director, Executive Director|
- BRIEF-Sun Pharmaceutical Industries says unit gets U.S. FDA nod for new label for odomzo (sonidegib)
- BRIEF-Sun Pharmaceutical Industries seeks shareholders' nod for re-appointment of Dilip S. Shanghvi as MD
- UPDATE 2-India's Sun Pharma reports Q1 loss as generics business suffers
- BRIEF-Sun Pharma says co on track to achieve $300 mln synergies from Ranbaxy deal
- BRIEF-Sun Pharmaceutical Industries posts June-qtr consol loss